Literature DB >> 29572685

[Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29572685     DOI： 10.1007/s00347-018-0680-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  93 in total

1.  A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.

Authors:  So Hyun Bae; Jang Won Heo; Cinoo Kim; Tae Wan Kim; Joo Yong Lee; Su Jeong Song; Tae Kwann Park; Sang Woong Moon; Hum Chung
Journal:  Am J Ophthalmol       Date:  2011-07-13       Impact factor: 5.258

2.  A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).

Authors:  Ehsan Rahimy; John D Pitcher; Jason Hsu; Murtaza K Adam; Abtin Shahlaee; Wasim A Samara; James F Vander; Richard S Kaiser; Allen Chiang; Marc J Spirn; Mitchell S Fineman
Journal:  Retina       Date:  2018-05       Impact factor: 4.256

3.  Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration.

Authors:  Eiko K de Jong; Myrte B Breukink; Rosa L Schellevis; Bjorn Bakker; Jacqueline K Mohr; Sascha Fauser; Jan E E Keunen; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon
Journal:  Ophthalmology       Date:  2014-11-06       Impact factor: 12.079

4.  Central serous chorioretinopathy in younger and older adults.

Authors:  R F Spaide; L Campeas; A Haas; L A Yannuzzi; Y L Fisher; D R Guyer; J S Slakter; J A Sorenson; D A Orlock
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

5.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

6.  Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2008-06-05       Impact factor: 12.079

7.  COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Cheng-Kuo Cheng; Chun-Kai Chang; Chi-Hsien Peng
Journal:  Retina       Date:  2017-02       Impact factor: 4.256

8.  Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea.

Authors:  Atul Kumar Jain; Andrew Kaines; Steven Schwartz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-01-05       Impact factor: 3.117

Review 9.  Central serous chorioretinopathy and glucocorticoids: an update on evidence for association.

Authors:  Benjamin P Nicholson; Elizabeth Atchison; Amrou Ali Idris; Sophie J Bakri
Journal:  Surv Ophthalmol       Date:  2017-06-30       Impact factor: 6.048

10.  Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.

Authors:  M de Gasparo; U Joss; H P Ramjoué; S E Whitebread; H Haenni; L Schenkel; C Kraehenbuehl; M Biollaz; J Grob; J Schmidlin
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030
View more
  1 in total

1.  Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.

Authors:  Vladimir Sheptulin; Konstantine Purtskhvanidze; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-10       Impact factor: 3.117
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.